Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Several new treatment combinations are being tested with checkpoint inhibitors, IDO1 inhibitors, tyrosine kinase inhibitors (TKIs), and VEGFR TKIs, explains Agarwal.

The way patients with newly diagnosed metastatic renal cell carcinoma are treated will be completely different in the next few years, says Agarwal.